Investors in Franco-Nevada Corp (Symbol: FNV) saw new options begin trading today, for the June 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 83 days until expiration the newly trading contract
Investors in Franco-Nevada Corp (Symbol: FNV) saw new options begin trading today, for the June 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 83 days until expiration the newly trading contract
Investors in Restaurant Brands International Inc (Symbol: QSR) saw new options become available today, for the June 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 83 days until expiration the newly a
Investors in Restaurant Brands International Inc (Symbol: QSR) saw new options become available today, for the June 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 83 days until expiration the newly a
Investors in TC Energy Corp (Symbol: TRP) saw new options begin trading today, for the June 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 83 days until expiration the newly trading contracts re
Investors in TC Energy Corp (Symbol: TRP) saw new options begin trading today, for the June 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 83 days until expiration the newly trading contracts re
Investors in Brookfield Corp (Symbol: BN) saw new options begin trading today, for the June 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 83 days until expiration the newly trading contracts re
Investors in Brookfield Corp (Symbol: BN) saw new options begin trading today, for the June 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 83 days until expiration the newly trading contracts re
Investors in Brookfield Asset Management Ltd (Symbol: BAM) saw new options become available today, for the June 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 83 days until expiration the newly avail
Investors in Brookfield Asset Management Ltd (Symbol: BAM) saw new options become available today, for the June 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 83 days until expiration the newly avail
U.S. President Donald Trump is likely to escalate the war with Iran, risking "1970s stagflation" if it does not go as planned, renowned economist and investor Nouriel Roubini told CNBC. Speaking to CNBC's Carolin Roth at the Ambrosetti Forum in Cernobbio, Italy on Friday, Roubini — best known for predicting the 2008 Global Financial Crisis — rejected the view that Trump was "looking desperately fo...
U.S. President Donald Trump is likely to escalate the war with Iran, risking "1970s stagflation" if it does not go as planned, renowned economist and investor Nouriel Roubini told CNBC. Speaking to CNBC's Carolin Roth at the Ambrosetti Forum in Cernobbio, Italy on Friday, Roubini — best known for predicting the 2008 Global Financial Crisis — rejected the view that Trump was "looking desperately for an off-ramp" to end the war. Markets have appeared optimistic in recent days about a potential resolution to the conflict. "People make the argument that … his polls are down, he wants this war to be over because there'll be damage for the economy, growth, inflation and the mid-term elections," he said, referring to congressional elections in November. "But if you think about it, the damage has already been done. If there is a ceasefire on conditions that are Iranian style, he's going to look like a loser — his credibility's weaker, he's going to lose the election for sure." "My argument is that, counterintuitively, he's going to decide to escalate," Roubini said of Trump. "He's going to escalate by taking over Kharg Island , continuing to bomb, with Israel, the leadership of Iran and the military structures." He outlined a scenario where "everything goes well, maybe the war lasts a little bit longer because of this escalation, but then you could have regime collapse." This could mean Oil prices might be higher in the short term, but a regime change — which Trump has called for in Iran — could deliver "a situation that is better for the world in terms of geopolitical stability," Roubini said. But he warned of another scenario where, after Trump escalates, "the Iranians are able to continue to block Hormuz or attack the oil facilities of the Gulf, then you end up in 1970s stagflation." "I think at this point he's going to escalate. From his point of view, it's worth taking that risk, given the option value of winning the war," he said. On Thursday evening, Trump said he wo...
Columbia Threadneedle Investments, an investment management company, released its fourth-quarter 2025 investor letter for “Columbia Global Technology Growth Fund”. A copy of the letter can be downloaded here. Markets advanced modestly higher in Q4 2025, with the S&P 500 returning 2.66%, the Nasdaq 100 gaining 2.47%, and the Dow Jones Industrial Average leading with a […]
Columbia Threadneedle Investments, an investment management company, released its fourth-quarter 2025 investor letter for “Columbia Global Technology Growth Fund”. A copy of the letter can be downloaded here. Markets advanced modestly higher in Q4 2025, with the S&P 500 returning 2.66%, the Nasdaq 100 gaining 2.47%, and the Dow Jones Industrial Average leading with a […]
Microglossum cyanobasis – or blue-based earthtongue – is only the second such specimen ever to be found in Europe The discovery of a rare, tongue-shaped fungus is being hailed as a sign of the crucial ecological value of England’s national nature reserves. Never before recorded in the UK, the blue-based earthtongue, also known as Microglossum cyanobasis , was found sprouting at the Kingley Vale na...
Microglossum cyanobasis – or blue-based earthtongue – is only the second such specimen ever to be found in Europe The discovery of a rare, tongue-shaped fungus is being hailed as a sign of the crucial ecological value of England’s national nature reserves. Never before recorded in the UK, the blue-based earthtongue, also known as Microglossum cyanobasis , was found sprouting at the Kingley Vale national nature reserve in West Sussex. Continue reading...
Force issues strongly worded rebuttal after Tory former cabinet minister alleges ‘egregious failures’ in call for review The police force that conducted the investigation into Lucy Letby has made a strongly worded public statement rejecting criticism after David Davis called in parliament for a review of the case. The Conservative former cabinet minister, who last year said that Letby had suffered...
Force issues strongly worded rebuttal after Tory former cabinet minister alleges ‘egregious failures’ in call for review The police force that conducted the investigation into Lucy Letby has made a strongly worded public statement rejecting criticism after David Davis called in parliament for a review of the case. The Conservative former cabinet minister, who last year said that Letby had suffered “a clear miscarriage of justice” , said Cheshire constabulary had approached the investigation into deaths of babies at the Countess of Chester hospital with too much focus on suspecting Letby, and made “egregious failures” in not following guidelines and best practice, including in the appointment of expert witnesses. Continue reading...
Bigpra/iStock via Getty Images Artesian Resources Corporation (NASDAQ: ARTNA ) is a water utility operating primarily in Delaware but also in Maryland and Pennsylvania. Artesian has been in the water business since 1905. In the past decade, its revenue has increased a little less than 50%, while the net income has nearly doubled. In addition, Artesian offers an attractive valuation and dividend yi...
Bigpra/iStock via Getty Images Artesian Resources Corporation (NASDAQ: ARTNA ) is a water utility operating primarily in Delaware but also in Maryland and Pennsylvania. Artesian has been in the water business since 1905. In the past decade, its revenue has increased a little less than 50%, while the net income has nearly doubled. In addition, Artesian offers an attractive valuation and dividend yield, a clear path to growth, and a solid balance sheet. Geographically focused water utility Artesian Resources is one of the smallest listed water utility companies in the U.S. Artesian’s market capitalization is only $340 million compared to the billions of some of its peers. Its water and wastewater systems serve over 300,000 people, primarily in Delaware. Artesian generates most of its revenue in water sales, while wastewater contributes less than 15% to sales. Artesian reported Q4 results on the 12th of March. Its annual revenue grew 4.6%, and net income increased 11.9%. Its earnings per share increased from $1.98 to $2.21. Data by YCharts A completion of a key project drives future growth In 2025 Artesian invested nearly $32 million (net, after contributions in aid of construction) in the water infrastructure. This year the company expects to invest another $64 million. That is nearly one-fifth of its market capitalization. The significant investments should carry earnings growth for several years to come. Data by YCharts The key ongoing project is the so-called SRRF wastewater treatment plant. Artesian inherited the project by acquiring Tidewater Environmental Services in 2022 from Middlesex Water Company. The second phase of the project is nearing its completion, and the third phase has received an approval, which will double the capacity compared to phase two. Last year its wastewater revenue grew approximately 11%. The further growth of wastewater sales will add to a more stable revenue base. Artesian’s water sales revenue increased 3.2% thanks to two temporary ra...
Citigroup is standing by its year-end outlook for the S&P 500 ( SP500 ), even as mounting geopolitical tensions and broader macroeconomic risks weigh on investor sentiment and push equities lower in 2026. In a recent note to clients, the bank reiterated its base-case target of 7,700 for the benchmark index, a forecast underpinned by projected earnings of roughly $320 per share—an estimate it now v...
Citigroup is standing by its year-end outlook for the S&P 500 ( SP500 ), even as mounting geopolitical tensions and broader macroeconomic risks weigh on investor sentiment and push equities lower in 2026. In a recent note to clients, the bank reiterated its base-case target of 7,700 for the benchmark index, a forecast underpinned by projected earnings of roughly $320 per share—an estimate it now views as potentially conservative. Citi also outlined a more optimistic scenario of 8,300, driven by stronger-than-expected profit growth and modest valuation expansion. On the downside, a bearish case of 5,700 reflects the possibility of weaker fundamentals and declining multiples. The firm acknowledged that the ongoing Iran-related conflict presents a fresh challenge to its outlook, adding to an already complex landscape shaped by artificial intelligence disruption risks, concerns within private credit markets, and lingering uncertainty around global trade policy. Despite these headwinds, Citi has not yet adjusted its projections, stating: “We maintain our full year targets for now.” The S&P 500 is currently trading near 6,417, down approximately 6.7% year to date. Achieving the bank’s base-case target would require a gain of about 20% from current levels, underscoring the extent of the potential rebound implied in its forecast. S&P 500 ETFs: ( SPY ), ( VOO ), ( IVV ), ( RSP ), ( SSO ), ( UPRO ), ( SH ), ( SDS ), ( SPXU ), ( FXAIX ), ( VFIAX ), ( VFFSX ), and ( SWPPX ). More on markets Dividend Roundup: Micron Technology, Cisco, Nucor, Freeport-McMoRan, and more Treasury Yields spike to multi-month highs as the 10-year tops 4.48% 20 dividend stocks to watch as the Middle East conflict continues to shake markets OECD lifts G20 inflation outlook as rising energy prices impact global markets Exxon Mobil tops Nvidia in valuation amid the ongoing Middle East conflict
Dr. David Fajgenbaum, one of the founders of Every Cure, a nonprofit focused on drug repurposing. Courtesy of Every Cure A version of this story first appeared in the CNBC Cures newsletter. Click here to sign up. There are over 10,000 rare diseases — 95% of which don't have a cure. It can cost billions of dollars and take more than a decade to develop a new treatment. Because patient populations i...
Dr. David Fajgenbaum, one of the founders of Every Cure, a nonprofit focused on drug repurposing. Courtesy of Every Cure A version of this story first appeared in the CNBC Cures newsletter. Click here to sign up. There are over 10,000 rare diseases — 95% of which don't have a cure. It can cost billions of dollars and take more than a decade to develop a new treatment. Because patient populations in the rare disease space can sometimes only consist of a few thousand — or even a few dozen people — drug companies have been hesitant to invest that kind of time and capital developing a drug that's unlikely to turn a profit. Drug repurposing flips that model on its head. Repurposing looks for new ways to use existing drugs to treat diseases that they weren't originally designed for. And now there are groups that are using AI to make that process more efficient. When Dr. David Fajgenbaum and his colleagues were looking to launch Every Cure, a non-profit focused on drug repurposing, they had a big decision to make. "If you want to repurpose drugs, there are two ways you can go. One is you can say, we are going to open up our shop and let patients and disease groups come to us and say, 'Hey, will you find a drug for my disease?'" Fajgenbaum said. "Or you take another approach ... using AI to find basically the lowest-hanging fruit across all drugs and all diseases." Fajgenbaum and his co-founders chose the second option. Every Cure doesn't search for a specific treatment for a specific disease. Instead, it looks to see if there are any existing drugs that can help any existing disease. The group looks for drug-disease matches, and then connects with the patients that can benefit. This marks a big departure from the way that rare disease treatments have traditionally been developed. "The way that research has always been done, if you want someone to do your research, you go to them, you give them money," Fajgenbaum said. "So people come to us, and they're like, we want you to...